When diagnosing lung metastases and second primary lung cancer in patients with head and neck cancer, low-dose CT leads to better sensitivity than chest x-ray but does not lead to improved overall ...
Head and neck squamous cell carcinomas responded better to a combination of two immunotherapies than to one immunotherapy ...
The researchers found that smoking duration and log cig-years demonstrated the strongest linear association with overall ...
Aprea Therapeutics Inc. has entered into a material transfer agreement with MD Anderson Cancer Center that will support investigation of APR-1051 as a potential treatment for head and neck squamous ...
Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.
Dr. Pan's broad research interest is novel anti-cancer target and molecule discovery using head and neck squamous cell carcinoma (HNSCC) as the model system. In the era of precision medicine, he ...
Ficerafusp alfa, a bifunctional antibody, targets EGFR and TGF-β, potentially offering anti-tumor activity in HNSCC patients. The FORTIFI-HN01 trial evaluates ficerafusp alfa with Keytruda in ...
Exosomal RNAs, including miRNA, mRNA, and lncRNA, are secreted by tumor cells and play a pivotal ... with head and neck squamous cell carcinoma (HNSCC) being the most common subtype.
[85,86] The EORTC is now planning a randomized Phase III study [107] in patients with locally advanced HPV/p16-negative HNSCC tumors with or without the hypoxic cell radiosensitizer nimorazole in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results